Arrowhead Pharmaceuticals (ARWR) Receivables - Other (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 12 years of Receivables - Other data on file, last reported at $9.8 million in Q4 2025.

• Quarterly Receivables - Other changed N/A year-over-year to $9.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.8 million (changed N/A YoY) and the FY2022 annual result came in at $4.8 million, up 4700.0% from the prior year.
• Receivables - Other rose to $9.8 million in Q4 2025, from $1.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $15.0 million in Q4 2022 to a low of $100000.0 in Q3 2021.
• A 4-year average of $4.2 million and a median of $1.4 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other tumbled 98.0% — and 2022, when it soared 4700.0%.
• Tracing ARWR's Receivables - Other over 4 years: stood at $100000.0 in 2021, then surged by 14900.0% to $15.0 million in 2022, then sank by 90.0% to $1.5 million in 2023, then jumped by 555.13% to $9.8 million in 2025.
• The last three Receivables - Other figures came in at $9.8 million (Q4 2025), $1.5 million (Q2 2023), and $15.0 million (Q4 2022), per Business Quant data.